Home › Funds › Affinity Asset Advisors, LLC › LXEO
Affinity Asset Advisors, LLC position in LXEO
LEXEO THERAPEUTICS INC · Health Care
Affinity Asset Advisors, LLC reported holding 7,245,611 shares of LXEO (LEXEO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$24.5M, representing 1.14% of its reported portfolio and ranking #26 among its reported holdings. Affinity Asset Advisors, LLC has disclosed LXEO holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's LXEO position evolved
Affinity Asset Advisors, LLC first disclosed a stake in LXEO in Q1 2025 at 1,480,881 shares (US$5.1M). The position peaked in Q4 2025 at 3,200,000 shares, worth US$31.8M. Across 7 filings, Affinity Asset Advisors, LLC increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 7,245,611 shares valued at US$24.5M — an increase of 1,438,000 shares quarter over quarter.. Notable position changes include a 142% increase in Q2 2025 (shares rose 65% over the following quarter), a 58% increase in Q1 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 1.48M | $5.14M | New |
| Q2 2025 | 3.59M | $14.43M | Add |
| Q3 2025 | 3.87M | $25.70M | Add |
| Q4 2025 | 3.20M | $31.78M | Reduce |
| Q1 2026 | 5.05M | $28.99M | Add |
| Q2 2026 | 5.81M | $27.03M | Add |
| Q3 2026 | 7.25M | $24.49M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LXEO and 13F data
LXEO (LEXEO THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in LXEO — the largest reported positions include MONTANOVA CAPITAL, LLC (US$29.7M), Frazier Life Sciences Management, L.P. (US$22.5M), Vestal Point Capital, LP (US$20.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LXEO
- MONTANOVA CAPITAL, LLC 6.38M sh · $29.72M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.82M sh · $22.46M · Q2 2026
- Vestal Point Capital, LP 4.32M sh · $20.11M · Q2 2026
- Paradigm Biocapital Advisors LP 4.18M sh · $19.44M · Q2 2026
- 683 Capital Management, LLC 1.88M sh · $8.73M · Q2 2026
- Avoro Capital Advisors LLC 1.49M sh · $6.93M · Q2 2026
- Spruce Street Capital LP 928.59K sh · $3.14M · Q3 2026
- Jones Hill Capital LP 593.74K sh · $2.01M · Q3 2026
- DAFNA Capital Management LLC 377.06K sh · $1.76M · Q2 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held LXEO?
Affinity Asset Advisors, LLC has disclosed LXEO holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is Affinity Asset Advisors, LLC's current position in LXEO?
As of Q3 2026, Affinity Asset Advisors, LLC holds 7.25M shares of LXEO (LEXEO THERAPEUTICS INC), valued at $24.49M, representing 1.14% of its reported portfolio and ranking #26.
Has Affinity Asset Advisors, LLC been buying or selling LXEO?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC increased its position in LXEO. The position peaked in Q4 2025 at 3.20M shares.
Which other funds hold LXEO?
Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Vestal Point Capital, LP, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.